Business Context and Reporting Period
Company: Surrozen, Inc. (SRZN)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Surrozen is a biotechnology company focused on discovering and developing product candidates that selectively modulate the Wnt pathway, primarily for ophthalmology indications such as diabetic macular edema (DME) and neovascular age-related macular degeneration (wet AMD). The company utilizes its proprietary SWAP (Surrozen Wnt signal Activating Protein) technology to create tissue-selective therapeutics.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $3.5 million | $10.7 million |
| Net Loss | $(242.0) million | $(63.6) million |
| Operating Expenses | $45.6 million | $36.2 million |
| Cash and Cash Equivalents (Year End) | $89.2 million | $34.6 million |
| Accumulated Deficit | $(527.3) million | $(285.3) million |
| Net Cash Used in Operating Activities | $(30.2) million | $(17.6) million |
| Net Cash Provided by Financing Activities | $85.1 million | $16.2 million |
Note: The 2025 Net Loss includes significant non-cash charges related to the fair value remeasurement of tranche liabilities and warrant liabilities.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 67% to $3.5 million. This was driven by the absence of the $10.0 million milestone payment from Boehringer Ingelheim recognized in 2024. However, research service revenue from a related party (TCGFB) increased to $3.5 million.
- Increased Operating Loss: Net loss widened significantly to $242.0 million from $63.6 million. This increase is primarily attributable to non-cash losses totaling approximately $178 million related to the 2025 Private Placement (PIPE), including a $71.1 million loss on execution and a $104.8 million loss on the change in fair value of tranche liability.
- Expense Growth: Research and Development (R&D) expenses increased 39% to $29.4 million due to higher manufacturing and lab costs for ophthalmology programs, partially offset by reduced clinical expenses following the discontinuation of the SZN-043 program. General and Administrative (G&A) expenses rose 8% to $16.2 million.
- Liquidity Improvement: Cash and cash equivalents increased from $34.6 million to $89.2 million, bolstered by $85.1 million in net financing proceeds from the 2025 PIPE and At-The-Market (ATM) offerings.
Guidance, Outlook, and Risks
Outlook and Milestones:
- SZN-8141: The company anticipates submitting an Investigational New Drug (IND) application in the second half of 2026. A second tranche of the 2025 PIPE, contingent on FDA clearance of this IND by October 31, 2026, could provide an additional $95.1 million in gross proceeds.
- Boehringer Ingelheim Collaboration: In March 2026 (subsequent to year-end), Boehringer Ingelheim achieved a research milestone for SZN-413, triggering a $5.0 million payment to Surrozen.
- Capital Runway: Management believes existing cash, plus proceeds received in early 2026, will fund operations for at least 12 months from the filing date.
Key Risks and Contingencies:
- Profitability: The company has a history of losses and expects to continue incurring significant losses for the foreseeable future. It has no approved products and no product sales revenue.
- Financing Needs: Substantial additional capital will be required to advance clinical trials. Failure to secure funding could force the company to delay, scale back, or discontinue development programs.
- Valuation Volatility: The company holds significant warrant and tranche liabilities classified as Level 3 fair value measurements. Changes in stock price and probability assumptions regarding milestone achievement can result in large non-cash gains or losses impacting the bottom line.
- Intellectual Property: In February 2026, Merck filed a post-grant review petition challenging one of Surrozen's patents related to its SWAP platform.
Investor Verification Checklist
- Capital Adequacy: Verify the sufficiency of the $89.2 million cash balance against the projected burn rate for advancing SZN-8141 and SZN-8143 into clinical trials.
- PIPE Contingency: Assess the probability of achieving the October 31, 2026, IND clearance milestone for SZN-8141, which is required to unlock the second tranche of $95.1 million in funding.
- Non-Cash Loss Impact: Review the sensitivity of the tranche liability and warrant liability valuations to changes in stock price and milestone probability, as these drove the majority of the 2025 net loss.
- Collaboration Revenue: Monitor the status of the Boehringer Ingelheim collaboration for SZN-413 and the potential for future milestone payments.
- Patent Challenges: Track the outcome of the post-grant review petition filed by Merck regarding the '278 patent, which covers the company's core SWAP platform technology.